* Vivos Therapeutics Inc VVOS.OQ VVOS.O is expected
to show a
fall in quarterly revenue when it reports results on August
14.
* The Littleton Colorado-based company is expected to
report a
0.9% decrease in revenue to $4.147 million from $4.18 million a
year ago, according to the mean estimate from 2 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for Vivos Therapeutics
Inc is
for a loss of 14 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Vivos
Therapeutics Inc is $1.95, above its last closing price
of $0.35.
This summary was machine generated August 12 at 02:04 GMT. All
figures in US dollars unless otherwise stated